Dietary Supplement Innovation Act
- Sponsor
- Rep. Harshbarger, Diana [R-TN-1]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 10, 2026
Bottom line
The bill aims to foster innovation and consumer access in the dietary supplement industry by loosening restrictions on ingredients that also have drug applications, while also making it harder for the FDA to enforce drug preclusion.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to clarify and expand the exceptions to the 'drug preclusion' rule, which generally prevents substances approved as drugs or undergoing clinical trials from being marketed as dietary supplements. It establishes new standards for evaluating whether a substance constitutes a drug for preclusion purposes, considering factors like dosage and route of administration. Crucially, it allows immediate judicial review of FDA assertions of drug preclusion and shifts the burden of proof to the government in such legal challenges.
Proponents argue
Supporters argue that the bill provides much-needed regulatory clarity and flexibility for the dietary supplement industry, encouraging innovation and ensuring consumers have access to a broader range of products. They contend it prevents the FDA from stifling innovation by inappropriately classifying substances with a history of safe use in supplements as drugs, and that it protects businesses from arbitrary regulatory actions by shifting the burden of proof.
Opponents contend
Critics might argue that the bill could undermine consumer safety by allowing drug-like substances into the less-regulated dietary supplement market without the rigorous safety and efficacy testing required for drugs. They may contend that shifting the burden of proof to the FDA weakens the agency's ability to protect public health and could lead to increased litigation, slowing down necessary enforcement actions.
The bill is short and relatively focused, making it accessible for a quick read to understand its core changes to the Federal Food, Drug, and Cosmetic Act.
Section 2(a)
Revised Drug Preclusion Rule for Foods and Dietary Supplements
This provision amends Section 301(ll) of the Federal Food, Drug, and Cosmetic Act to expand the circumstances under which a substance that is an approved drug, a licensed biological product, or undergoing Phase 2 or 3 clinical investigations can still be added to food or dietary supplements. New exceptions include prior marketing as food or a dietary supplement before drug approval or clinical trials, inactive or withdrawn clinical investigations for at least seven years, or if the substance is used to enhance food safety without independent biological effects.
Supporters argue
Supporters argue this clarification fosters innovation in the dietary supplement industry and ensures consumers have access to a broader range of products. They contend it addresses concerns that the existing rule stifles innovation by preventing substances with a history of safe use in supplements from being marketed if they later become drugs, even if their use in supplements is distinct.
Critics contend
Critics might argue that this could undermine the drug approval process, potentially allowing substances into supplements without the rigorous safety and efficacy testing required for drugs, raising consumer safety concerns. They may contend it creates a loophole for substances that should be regulated as drugs, blurring the lines between pharmaceuticals and supplements.
Tradeoffs
This provision balances encouraging innovation and consumer access in the dietary supplement market against maintaining the integrity and safety standards of the drug approval process. It navigates the tension between allowing natural substances to be marketed as supplements and preventing companies from circumventing drug regulations.
Section 2(b) (new Section 413A(a))
Standards for Determining Drug Preclusion
This section directs the Secretary of Health and Human Services (via the FDA) to consider specific differences when determining if a drug has been 'added' to a food or dietary supplement for preclusion purposes. These differences include the route of administration, recommended dosage, concentration or composition, and the degree of safety of the substance when added to food or a dietary supplement. This means a substance might be a drug in one form but a permissible supplement ingredient in another.
Section 2(b) (new Section 413A(b))
Immediate Judicial Review and Shifted Burden of Proof for Drug Preclusion Assertions
This provision allows for immediate judicial review of any FDA warning letter, response, or statement asserting that a food or dietary supplement violates the drug preclusion rule, regardless of whether it's considered a 'final agency action.' Furthermore, in any such legal action, the United States (i.e., the FDA) will bear the burden of proof to show that a violation has occurred.
Section 2(c)
Conforming Changes to Definition of Dietary Supplement
This section makes conforming amendments to Section 201(ff) of the Federal Food, Drug, and Cosmetic Act, which defines 'dietary supplement.' Specifically, it strikes the clause that effectively excluded a dietary ingredient from being a dietary supplement if it was an approved drug or subject to investigation before being marketed as a supplement, unless it was grandfathered. This change aligns the definition of a dietary supplement with the new, broader exceptions established in Section 2(a) regarding drug preclusion.
This section makes conforming amendments to the definition of 'dietary supplement' in Section 201(ff) of the Federal Food, Drug, and Cosmetic Act. Specifically, it strikes subparagraph (3), which previously stated that a dietary ingredient could not be a dietary supplement if it was an approved drug or subject to investigation before being marketed as a supplement, unless it was marketed before October 15, 1994 (the 'grandfathered drug' exception).
Section 2(c)
Why it matters:This is standard legislative practice for technical adjustments necessary to align different parts of a statute after substantive changes have been made elsewhere in the bill. While technically buried, its purpose is to ensure internal consistency.
Case for: Supporters argue this amendment is essential for legal consistency, ensuring the definition of a dietary supplement aligns with the new, broader exceptions to drug preclusion established in Section 2(a). Without it, there could be conflicting interpretations of what qualifies as a dietary supplement, leading to regulatory confusion.
Case against: Critics might argue that while presented as a technical fix, this change fundamentally alters the historical understanding of what constitutes a dietary supplement. By removing the explicit 'grandfathered drug' exception, it could be seen as further blurring the lines between drugs and supplements, potentially allowing more drug-like substances into the market without sufficient regulatory oversight.
Estimated impact: Clarifies the legal status of a wide range of ingredients for the dietary supplement industry, potentially enabling the marketing of substances that were previously ambiguous or explicitly excluded under the old definition. This could have a broad impact on product development and market offerings.